Research: Pancreatic cancer clinical trials and research studies

MIPPaC: Understanding the mechanisms underlying weight loss in people with cancer by investigating changes to metabolism and the immune system

PORTICO-Trans: A feasibility study looking at the immune system in tumours, comparing samples collected during surgery to those taken afterwards

PaCE: Evaluating molecular biomarkers to risk stratify pancreatic cystic lesions

GRECO-2: A Randomised, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer

Portico-SABR: Investigate the effects and safety of SABR treatment given to patients with operable pancreatic cancer prior to surgery to remove the tumour

daNIS-2: A randomised, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation

ATRiUM: A Phase I clinical trial looking at AZD6738 (ATR inhibitor) in combination with Gemcitabine

Porcupine 2: A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care who have the RNF43 rearrangement.